Insider Buying: Scancell Holdings plc (LON:SCLP) Insider Buys 4,400,000 Shares of Stock

Key Points

• Insider Martin Diggle purchased 4,400,000 shares of Scancell Holdings plc at an average price of GBX 10 ($0.13), totaling approximately £440,000 ($584,251.76).
• Scancell stock opened at GBX 10.90 ($0.14) with a 12-month range between GBX 7.26 ($0.10) and GBX 19.75 ($0.26), indicating considerable volatility in its value.
• Scancell is a clinical stage immunotherapy biotech firm focused on developing innovative cancer treatments to address significant unmet needs in the oncology sector.

Scancell Holdings plc (LON:SCLP - Get Free Report) insider Martin Diggle bought 4,400,000 shares of Scancell stock in a transaction that occurred on Friday, August 1st. The shares were acquired at an average price of GBX 10 ($0.13) per share, for a total transaction of £440,000 ($584,251.76).

Martin Diggle also recently made the following trade(s):

• On Tuesday, May 20th, Martin Diggle bought 44,944 shares of Scancell stock. The shares were acquired at an average price of GBX 9 ($0.12) per share, for a total transaction of £4,044.96 ($5,371.08).

Scancell Stock Performance

Scancell stock opened at GBX 10.90 ($0.14) on Monday. Scancell Holdings plc has a 12-month low of GBX 7.26 ($0.10) and a 12-month high of GBX 19.75 ($0.26). The company has a market capitalization of £112.89 million, a price-to-earnings ratio of -16.71 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The firm's fifty day moving average price is GBX 9.91 and its 200 day moving average price is GBX 9.43.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.